



For further information:
Investor Relations (Tel: +34 91 244 44 22)
Marta Campos Martínez mcampos@rovi.es

ROVI announces the agreement with Sandoz to distribute and market its Enoxaparin biosimilar

Madrid, 11th June 2018 – Laboratorios Farmacéuticos Rovi S.A. (ROVI:SM) signed a licensing agreement with **Sandoz**, a division of **Novartis AG** and a global leader in generic pharmaceuticals and biosimilars, to distribute and market its enoxaparin biosimilar in **14 countries/regions** (Australia, New Zealand, Philippines, Hong Kong, Singapore, Vietnam, Malaysia, Canada, South Africa, Brazil, Colombia, Argentina, Mexico and Central America). Under the terms of the agreement, Sandoz has the exclusive rights for three of these countries, which are Hong Kong, Singapore and Vietnam.

ROVI's enoxaparin sodium is a biosimilar to Sanofi's Lovenox® and Clexane®, which is an anticoagulant medication that belongs to low molecular weight heparin class. It is used to treat and prevent deep vein thrombosis and pulmonary embolism. As of March 2018, ROVI has achieved national authorisation for their biosimilar of enoxaparin in 16 European markets, and has commenced marketing in Germany and UK.

Juan López-Belmonte Encina, ROVI's Chief Executive Officer said, "ROVI is very excited with our agreement with Sandoz, the global leader in biosimilars where our enoxaparin biosimilar will find an excellent growth. Sandoz is an excellent collaboration partner to expand ROVI's global footprint and become a leader in the low-molecular-weight heparin field"

About ROVI

ROVI is a fully integrated Spanish specialty pharmaceutical company engaged in the research, development, in-licensing, manufacturing and marketing of small molecule and specialty biologic drugs. The Company has a diversified portfolio of products that it markets in Spain through its specialized sales force, calling on specialist physicians, hospitals and pharmacies. ROVI's portfolio of 30 principal marketed products is currently anchored by the internally-developed, second generation low molecular weight heparin, Bemiparin. ROVI's research and development pipeline is focused primarily on the expansion of applications, indications and alternative mechanisms of action for the heparin-derived products and other glycosaminoglycans and on the development of new controlled release mechanisms based on ISM® technology, with the aim of obtaining new pharmaceutical products that enable the regular administration of formulations which are administered daily in chronic and prolonged treatments. ROVI manufactures the active biological ingredient (Bemiparin) for its principal proprietary products and for injectable pharmaceutical products developed by its in-house research team, and utilizes its state-of-the-art filling and packaging capabilities to provide a broad array of toll manufacturing services to leading international pharmaceutical companies, primarily in the area of pre-filled syringes. In addition, ROVI provides contract manufacturing and packaging services of solid oral pharmaceutical dosage forms, using the most enhanced technology, Roller Compaction. Additional information about ROVI is available on the company's website: www.rovi.es.